Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,153
archived clinical trials in
Gout

Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Little Rock, AR
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Little Rock, AR
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Honolulu, HI
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Honolulu, HI
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Jeffersonville, IN
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jeffersonville, IN
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Louisville, KY
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Louisville, KY
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Jackson, MS
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jackson, MS
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Omaha, NE
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Omaha, NE
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Albuquerque, NM
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albuquerque, NM
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Sioux Falls, SD
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Sioux Falls, SD
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Ogden, UT
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ogden, UT
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral BCX4208 Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management
Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management
Status: Archived
Umass Memorial Medical Center
mi
from
Worcester, MA
Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management
Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management
Status: Archived
Updated: 1/1/1970
Umass Memorial Medical Center
mi
from
Worcester, MA
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Decatur, GA
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dunwoody, GA
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dunwoody, GA
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Marietta, GA
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Norcross, GA
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Norcross, GA
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Roswell, GA
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Roswell, GA
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Suwanee, GA
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Suwanee, GA
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Waycross, GA
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Waycross, GA
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Honolulu, HI
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boise, ID
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Coeur D'Alene, ID
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nampa, ID
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nampa, ID
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Addison, IL
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Addison, IL
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Arlington Heights, IL
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Evanston, IL
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Evergreen Park, IL
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Flossmoor, IL
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Flossmoor, IL
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Melrose Park, IL
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Melrose Park, IL
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Morton, IL
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Morton, IL
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Naperville, IL
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Naperville, IL
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Quincy, IL
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Quincy, IL
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rockford, IL
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rockford, IL
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bloomington, IN
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bloomington, IN
Click here to add this to my saved trials
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Brownsburg, IN
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Brownsburg, IN
Click here to add this to my saved trials